Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 07 2018 - 04:30PM
Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage
biopharmaceutical company focused on the development of novel
therapeutic compounds to treat disease through the inhibition of
the complement system, today announced that the Company will
present at the following investor conferences in November:
- Credit Suisse 27th Annual Healthcare Conference on Tuesday,
November 13, 2018 at 2:50 p.m. MST (4:50 p.m. ET) in Scottsdale,
AZ
- Evercore ISI HealthConX Conference on Wednesday, November 28,
2018 at 4:35 p.m. ET in Boston, MA
Both presentations will be given by Apellis founder and chief
executive officer Cedric Francois, MD, PhD, and available via live
webcast from the “Events and Presentations” page of the “Investors
and Media” section of the Company’s website at
http://investors.apellis.com/events-and-presentations. A replay of
the webcasts will be available for 90 days following the
events.
About ApellisApellis Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company focused on the development
of novel therapeutic compounds for the treatment of a broad range
of life-threatening or debilitating autoimmune diseases based upon
complement immunotherapy through the inhibition of the complement
system at the level of C3. Apellis is the first company to advance
chronic therapy with a C3 inhibitor into clinical trials. For
additional information about Apellis and APL-2, please visit
http://www.apellis.com. For additional information regarding our
clinical trials, visit www.apellis.com/clinical-trials.html.
Forward-Looking Statements Statements in
this press release about future expectations, plans and prospects,
as well as any other statements regarding matters that are not
historical facts, may constitute “forward-looking statements”
within the meaning of The Private Securities Litigation Reform Act
of 1995. These statements include, but are not limited to,
statements relating to the implications of preliminary clinical
data. The words “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Actual results may differ materially from
those indicated by such forward-looking statements as a result of
various important factors, including: whether preliminary or
interim results from a clinical trial will be predictive of the
final results of the trial; whether results obtained in preclinical
studies and clinical trials such as the results reported in this
release will be indicative of results that will be generated in
future clinical trials; whether APL-2 will successfully advance
through the clinical trial process on a timely basis, or at all;
whether the results of such clinical trials will warrant regulatory
submissions and whether APL-2 will receive approval from the United
States Food and Drug Administration or equivalent foreign
regulatory agencies for GA, PNH or any other indication; whether,
if Apellis’ products receive approval, they will be successfully
distributed and marketed; and other factors discussed in the “Risk
Factors” section of Apellis’ Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on July 31, 2018 and
the risks described in other filings that Apellis may make with the
Securities and Exchange Commission. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Apellis specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Media Contact:Tully
Nicholastnicholas@denterlein.com 617.482.0042
(office)860.490.0218 (mobile)
Investor Contact:Alex
Kaneakane@w2ogroup.com 212.301.7218
(office)929.400.2691 (mobile)
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2023 to Mar 2024